文章摘要
王淑琴,高怡青,朱磊,等.新生儿糖尿病 6例病例特点及临床分析[J].安徽医药,2023,27(2):280-284.
新生儿糖尿病 6例病例特点及临床分析
Characteristics and clinical analysis of 6 cases of neonatal diabetes mellitus
  
DOI:10.3969/j.issn.1009-6469.2023.02.015
中文关键词: 新生儿糖尿病  格列本脲  临床特征  KCNJ11基因
英文关键词: Neonatal diabetes mellitus  Glibenclamide  Clinical features  KCNJ11
基金项目:徐州市卫生健康委科技项目面上项目( XWKYHT20200033)
作者单位E-mail
王淑琴 徐州医科大学附属徐州儿童医院 内分泌遗传代谢科江苏徐州 221000  
高怡青 徐州医科大学附属徐州儿童医院 内分泌遗传代谢科江苏徐州 221000 gaoyiqing0206@163.com 
朱磊 徐州医科大学附属徐州儿童医院 重症医学科江苏徐州 221000  
侯梦 徐州医科大学附属徐州儿童医院 内分泌遗传代谢科江苏徐州 221000  
刘金凤 徐州医科大学附属徐州儿童医院 新生儿科江苏徐州 221000  
薛颖 徐州医科大学附属徐州儿童医院 内分泌遗传代谢科江苏徐州 221000  
摘要点击次数: 944
全文下载次数: 302
中文摘要:
      目的总结 6例新生儿糖尿病( neonatal diabetes mellitus,NDM)的临床特点及随访资料,为临床诊疗提供参考。方法对 2013年 2月至 2021年 6月就诊于徐州医科大学附属徐州儿童医院内分泌科 6例 NDM病儿的临床特征、诊疗经过等进行回顾性分析。结果病儿诊断年龄范围为 3~256 d,随访时间范围为 4.5~102.2个月。反应差起病 3例,发热感染起病 3例。初诊时 4例合并糖尿病酮症酸中毒, 1例合并糖尿病酮症。急性期胰岛素治疗血糖控制良好。 5例行格列本脲经验性治疗, 4例有效, 1例无效停药,经基因检测证实格列本脲治疗有效为 KCNJ11基因突变,其中 1例基因突变为首次报道。 4例使用格列本脲病儿随访至今血糖均控制良好, 1例随访至 6月龄停格列本脲, 8岁复发后予胰岛素治疗。结论格列本脲对 KCNJ11基因突变 NDM治疗有效,长期随访安全。 TNDM缓解后可出现复发,复发后可予胰岛素治疗。
英文摘要:
      Objective To summarize the clinical characteristics and follow-up data of 6 cases of neonatal diabetes mellitus (NDM), so as to provide reference for clinical diagnosis and treatment.Methods The clinical characteristics, diagnosis and treatment of 6 chil-dren with NDM in the Department of Endocrinology, Xuzhou Children's Hospital Affiliated to Xuzhou Medical University from Febru-ary 2013 to June 2021 were analyzed retrospectively.Results The age of diagnosis was 3-256 days and the follow-up was 4.5-102.2 months. There were 3 cases of poor response and 3 cases of fever infection. At the initial diagnosis, 4 cases had diabetic ketoacidosisand 1 cases had diabetic ketosis. Blood glucose was well controlled by insulin treatment in acute stage. Five cases were treated withglibenclamide empirically, 4 cases were effective and 1 case was ineffective. Gene test confirmed that the effective treatment of gliben-clamide was KCNJ11 gene mutation, of which 1 gene mutation was reported for the first time. The blood glucose of 4 children treatedwith glibenclamide was well controlled since follow-up. One case stopped glibenclamide after follow-up to 6 months, relapsed at the age of 8 years and was treated with insulin.Conclusion Glibenclamide is effective in the treatment of NDM with KCNJ11 gene mutation.TNDM relapses after remission, and insulin treatment can be given after recurrence.
查看全文   查看/发表评论  下载PDF阅读器
关闭

分享按钮